MeiraGTx at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
MeiraGTx brings 3 presentations to ESGCT 2026 in Hamburg. Its contributions cover AAV characterisation and potency, including mass spectrometry for critical quality attributes and a commercial activity assay for an aquaporin gene therapy for dry mouth. Another strand rescues retinal pigment epithelium cells under oxidative stress with AAV-NRF2.
| Organization | ESGCT 2026 Attendance |
|---|---|
MeiraGTx New York, NY | |
Clinical-stage gene therapy company with AAV programs, riboswitch-controlled gene expression and its own vector manufacturing. | Poster Wed Oct 28 1:30pm–3:30pm Denaturing size exclusion chromatography-MS for characterisation of AAV and assessment of CQAs Poster Thu Oct 29 2:00pm–4:00pm A commercial in-vitro biological activity potency assay for AAV-AQP1 treatment of Xerostomia Poster Thu Oct 29 2:00pm–4:00pm AAV-NRF2 rescues RPE cell function and viability in human IPSC-derived and mouse models of oxidative stress |
Instantly find 20 buyers from MeiraGTx
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction